Roots Analysis has done a detailed study on RNAi
Therapeutics Market (2nd Edition), 2019-2030 covering key aspects
of the industry’s evolution and identifying potential future growth
opportunities.
To order this 350+ page report, which features 130+ figures
and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Key Market Insights
§
Over 32,000 patents related to RNAi therapeutics,
indicating the heightened pace of research, have been filed / granted in the
last several years
§
Presently, there is only one approved drug and over 150
product candidates, which are being evaluated for the treatment of a variety of
disease indications, based on the RNAi principle
§
In order to achieve a competitive edge, the drug developers
are increasingly focusing on developing the robust pipeline molecules across
different therapeutic areas
§
Majority of the candidate therapies are currently in the
early stages of development and are based on the siRNA approach; the innovation
in this domain is being led by developers headquartered in the US
§
Several trials evaluating various
RNAi drug candidates against a wide range of therapeutic indications have been
registered in the recent past
§
Investors, having realized the opportunity within this emerging
segment of the pharmaceutical industry, have invested over USD 5 billion in
capital across 65 instances, in the period between 2014 and 2019
§
The increasing interest in this
field is reflected in recent partnership activity; majority of deals inked were
R&D and licensing agreements, featuring the participation of both
international and indigenous stakeholders
§
In order to keep patients and healthcare professionals
informed and aware of the developments in this field of medicine, companies are
deploying diverse promotional strategies for their respective products
§
Prevalent trends indicate that the market for RNAi
therapeutics is poised to grow significantly as multiple late stage molecules
are commercialized in the near future, for the treatment of different clinical
conditions
For
more information, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Table of Contents
1 PREFACE
1.1. Scope of the
Report
1.2. Research
Methodology
1.3. Chapter
Outlines
2 EXECUTIVE
SUMMARY
3 INTRODUCTION
3.1. Chapter
Overview
3.2. Historical
Trends
3.2.1. Discovery of
RNAi
3.2.2. RNAi Therapy
Development Efforts
3.3. Mechanism of
RNAi
3.3.1. Components of
RNAi
3.3.2. Cellular
Mechanism
3.4. Types of RNAi
Molecules
3.4.1. siRNA
3.4.2. miRNA
3.4.3. shRNA
3.5. Applications
of RNAi
3.6. Advantages
and Disadvantages of RNAi
3.7. Regulatory
Guidelines
3.8. Future
Perspectives
4 COMPETITIVE
LANDSCAPE
4.1. Chapter
Overview
4.2. Marketed and
Development Pipeline
4.2.1. Analysis by
Type of RNAi Molecule
4.2.2. Analysis by
Phase of Development
4.2.3. Analysis by
Type of Target Gene
4.2.4. Analysis by
Therapeutic Area
4.2.5. Analysis by
Route of Administration
4.2.6. Analysis by
Special Drug Designation
4.2.7. Key Players
4.3. Developer
Landscape
4.3.1. Analysis by
Year of Establishment
4.3.2. Analysis by
Company Size
4.3.3. Analysis by
Location of Headquarters
5 COMPANY
COMPETITIVENESS ANALYSIS
5.1. Chapter
Overview
5.2. Methodology
5.3. Assumptions
and Key Parameters
5.4. Competitiveness
Analysis
6 LATE STAGE
RNAi THERAPEUTICS
6.1. Chapter
Overview
6.2. Onpattro®
6.2.1. Drug Overview
6.2.2. Technology
Overview
6.2.3. Current
Development Status
6.2.4. Recent
Clinical Trial Results
6.3. ARO-AAT
6.3.1. Drug Overview
6.3.2. Technology
Overview
6.3.3. Current
Development Status
6.3.4. Recent Clinical
Trial Results
6.4. Fitusiran
6.4.1. Drug Overview
6.4.2. Technology
Overview
6.4.3. Current
Development Status
6.4.4. Recent
Clinical Trial Results
6.5. Givosiran
6.5.1. Drug Overview
6.5.2. Technology
Overview
6.5.3. Current
Development Status
6.5.4. Recent
Clinical Trial Results
6.6. Inclisiran
6.6.1. Drug Overview
6.6.2. Technology
Overview
6.6.3. Current
Development Status
6.6.4. Recent
Clinical Trial Results
6.7. Lumasiran
6.7.1. Drug Overview
6.7.2. Technology
Overview
6.7.3. Current
Development Status
6.7.4. Recent
Clinical Trial Results
6.8. QPI-1002
6.8.1. Drug Overview
6.8.2. Technology
Overview
6.8.3. Current
Development Status
6.8.4. Recent
Clinical Trial Results
6.9. SYL 1001
6.9.1. Drug Overview
6.9.2. Technology Overview
6.9.3. Current
Development Status
6.9.4. Recent
Clinical Trial Results
6.10. Vigil-EWS
6.10.1. Drug Overview
6.10.2. Technology
Overview
6.10.3. Current
Development Status
6.10.4. Recent
Clinical Trial Results
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
